Tell A Colleague / Friend

CSL Biotherapies, and its parent company, CSL Limited have reached an agreement with Merck & Co., Inc. on rights to market and distribute Afluria^® in the United States under an exclusive, six-year agreement effective September 3, 2009. Merck has the exclusive right to sell and distribute Afluria^® in the United States beginning with the 2010-2011 influenza season. The manufacture, filling and packaging of Afluria^® will continue and will not change with this agreement; CSL Ltd. will retain the Afluria^® license.

For information on prebooking Afluria^® for the 2010-2011 season, please visit www.merckvaccines.com/afluria or call the Merck Vaccine Customer Center at 877-829-6372.

For any questions relating to Afluria^® 2009-2010, please contact 1-888-435-8633 or CustomerSupport@cslbiotherapies.com.

Afluria^® 2009-2010 Prescribing Information (Revised 11/2009)

CSL Biotherapies' plans or capacity for manufacturing and delivering its pandemic Influenza A (H1N1) Monovalent Vaccine to US Human Health Services (HHS) are not affected by the seasonal influenza vaccine agreement. For any questions relating to CSL Biotherapies' Influenza A (H1N1) 2009 Monovalent Vaccine, please contact 1-888-435-8633 or CustomerSupport@cslbiotherapies.com.

CSL Biotherapies' Influenza A (H1N1) 2009 Monovalent Vaccine Prescribing Information

Share with a Colleague

Recommend Afluria.com

If you would like to recommend Afluria^® to a colleague, simply provide the person's name and e-mail address, and we'll contact them for you. If you wish, you can include a personal message.

Your name: *

Your e-mail address: *

Enter your colleague's
e-mail address: *

Enter your message (optional):

* Required information